The same was true for ORR, with similar results between mTOR inhibitors and other treatments, in all the patients (16.7% vs. 15.4%, P = 0.99), in malignant PEComa only (13.6% vs. 16.7%, P = 0.99), and in AML/LAM only (P = 0.99). The gene discussed is MTOR; the disease is acute myeloid leukemia.